PMID- 36449401
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230529
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 32
IP  - 5
DP  - 2023 May
TI  - Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors 
      reboxetine and atomoxetine for the treatment of schizophrenia and attention 
      deficit hyperactivity disorder.
PG  - 511-522
LID - 10.17219/acem/155802 [doi]
AB  - BACKGROUND: Norepinephrine transporter inhibitors that can alter the level of 
      neurotransmitter in the brain are used to treat neurological disorders. However, 
      a number of studies have reported their limited significance as a result of their 
      slow onset of action and moderate efficacy. OBJECTIVES: To determine the effects 
      of norepinephrine reuptake inhibitors (NRIs), reboxetine and atomoxetine on 
      schizophrenia and attention deficit hyperactivity disorder (ADHD). MATERIAL AND 
      METHODS: Relevant articles published between 2000 and 2022 were searched in the 
      MEDLINE, CINAHL (via Ebsco), Web of Science and Scopus databases. Among the 
      various NRIs, studies concerning the 2 potent drugs - reboxetine and atomoxetine 
      - were selected for analysis. Odds ratios (ORs) with 95% confidence intervals 
      (95% CIs) were estimated, along with the exploration of heterogeneity and 
      publication bias, using RevMan software. RESULTS: A total of 14 eligible studies 
      with a combined sample size of 970 patients were included. Using a random effects 
      model, an OR of 0.55 (0.32-0.94), a Tau2 value of 0.23, a /2 value of 12.31, 8 
      degrees of freedom (df), an I2 of 35%, a Z value of 2.19, and a p-value of 0.03 
      were recorded for reboxetine. Atomoxetine had an OR of 0.35 (0.13-0.97), a Tau2 
      value of 0.58, a /2 value of 7.31, 4 df, an I2 of 45%, a Z value of 1.53, and a 
      p-value of 0.04. All results were statistically significant with a low risk of 
      publication bias, as was evident from the p-values >0.05 derived from the Egger's 
      test and the Begg's test. These drugs provided comparable changes to control 
      drugs in Hamilton Depression Rating Scale (HAM-D) scores, Positive and Negative 
      Syndrome Scale (PANSS) scores and ADHD ratings. This confirms the efficacy of 
      reboxetine for the treatment of schizophrenia and atomoxetine for the treatment 
      of ADHD. CONCLUSION: The present meta-analysis suggests that NRIs are efficacious 
      and therefore they are potential candidate drugs for the treatment of 
      schizophrenia and ADHD.
FAU - Hu, Xiaojing
AU  - Hu X
AD  - Department of Psychiatry, Shandong Mental Health Center, Shandong University, 
      Jinan, China.
FAU - Pan, Lili
AU  - Pan L
AD  - Department of Psychology, Taian Traditional Chinese Medicine Hospital, China.
FAU - Li, Wenjie
AU  - Li W
AD  - Department of Psychiatry, Shandong Mental Health Center, Shandong University, 
      Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 57WVB6I2W0 (Atomoxetine Hydrochloride)
RN  - 947S0YZ36I (Reboxetine)
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Humans
MH  - Atomoxetine Hydrochloride/therapeutic use
MH  - *Attention Deficit Disorder with Hyperactivity/drug therapy
MH  - Reboxetine/therapeutic use
MH  - *Schizophrenia/drug therapy
MH  - Adrenergic Uptake Inhibitors/therapeutic use
MH  - Norepinephrine/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - atomoxetine
OT  - attention deficit hyperactivity disorder
OT  - neurological disorders
OT  - reboxetine
OT  - schizophrenia
EDAT- 2022/12/01 06:00
MHDA- 2023/05/29 06:41
CRDT- 2022/11/30 13:03
PHST- 2023/05/29 06:41 [medline]
PHST- 2022/12/01 06:00 [pubmed]
PHST- 2022/11/30 13:03 [entrez]
AID - 10.17219/acem/155802 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2023 May;32(5):511-522. doi: 10.17219/acem/155802.